{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:18:14Z","timestamp":1792505894219,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07430-x","type":"journal-article","created":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:07:57Z","timestamp":1785557277000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: a systematic review of diabetic retinopathy outcomes"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3152-542X","authenticated-orcid":false,"given":"Catarina","family":"Francisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o S\u00e9rgio","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Laiginhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,1]]},"reference":[{"key":"7430_CR1","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee (2024) Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes-2024. Diabetes Care 47:S52\u2013S76. https:\/\/doi.org\/10.2337\/dc24-S004","DOI":"10.2337\/dc24-S004"},{"key":"7430_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","volume":"44","author":"S Feldman-Billard","year":"2018","unstructured":"Feldman-Billard S, Larger E, Massin P, Standards for screeningand surveillance of ocular complications in people with diabetes SFDsg (2018) Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab 44:4\u201314. https:\/\/doi.org\/10.1016\/j.diabet.2017.10.014","journal-title":"Diabetes Metab"},{"key":"7430_CR3","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102. https:\/\/doi.org\/10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"7430_CR4","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"7430_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s40261-023-01319-x","volume":"43","author":"X Jiao","year":"2023","unstructured":"Jiao X, Peng P, Zhang Q, Shen Y (2023) Glucagon-like peptide-1 receptor agonist and risk of diabetic retinopathy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Drug Investig 43:915\u2013926. https:\/\/doi.org\/10.1007\/s40261-023-01319-x","journal-title":"Clin Drug Investig"},{"key":"7430_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","volume":"68","author":"I Kapoor","year":"2023","unstructured":"Kapoor I, Sarvepalli SM, D\u2019Alessio D, Grewal DS, Hadziahmetovic M (2023) Glp-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials. Surv Ophthalmol 68:1071\u20131083. https:\/\/doi.org\/10.1016\/j.survophthal.2023.07.002","journal-title":"Surv Ophthalmol"},{"key":"7430_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","volume":"21","author":"D Zheng","year":"2023","unstructured":"Zheng D, Li N, Hou R, Zhang X, Wu L, Sundquist J et al (2023) Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and mendelian randomization studies. BMC Med 21:40. https:\/\/doi.org\/10.1186\/s12916-023-02753-6","journal-title":"BMC Med"},{"key":"7430_CR8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsboll","year":"2018","unstructured":"Vilsboll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simo R et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20:889\u2013897. https:\/\/doi.org\/10.1111\/dom.13172","journal-title":"Diabetes Obes Metab"},{"key":"7430_CR9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"S Marso","year":"2016","unstructured":"Marso S, Daniels G, Brown-Frandsen K (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes (leader). N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"10193","key":"7430_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/s0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"13","key":"7430_CR11","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/s0140-6736(17)32135-3","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. New England J Med 377(13):1228\u20131239. https:\/\/doi.org\/10.1016\/s0140-6736(17)32135-3","journal-title":"New England J Med"},{"key":"7430_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/s2213-8587(18)30006-0","volume":"6","author":"A Hernandez","year":"2018","unstructured":"Hernandez A, Green J, Janmohamed S (2018) Albiglutide and cardiovascular outcomes in type 2 diabetes and cardiovascular disease (harmony outcomes). Lancet Diabetes Endocrinol 6:817\u2013828. https:\/\/doi.org\/10.1016\/s2213-8587(18)30006-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7430_CR13","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","volume":"54","author":"I Dicembrini","year":"2017","unstructured":"Dicembrini I, Nreu B, Scatena A, Andreozzi F, Sesti G, Mannucci E et al (2017) Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933\u2013941. https:\/\/doi.org\/10.1007\/s00592-017-1031-9","journal-title":"Acta Diabetol"},{"key":"7430_CR14","doi-asserted-by":"publisher","first-page":"e2526321","DOI":"10.1001\/jamanetworkopen.2025.26321","volume":"8","author":"DJ Ramsey","year":"2025","unstructured":"Ramsey DJ, Makwana B, Dani SS, Patel M, Panchal K, Shah J et al (2025) Glp-1 receptor agonists and sight-threatening ophthalmic complications in patients with type 2 diabetes. JAMA Netw Open 8:e2526321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.26321","journal-title":"JAMA Netw Open"},{"issue":"19","key":"7430_CR15","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"New England J Med"},{"key":"7430_CR16","doi-asserted-by":"publisher","first-page":"108472","DOI":"10.1016\/j.jdiacomp.2023.108472","volume":"37","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, Vernstrom L, Sorensen SS, Funck KL, Petersen L, Bek T et al (2023) Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: a prespecified secondary analysis of a randomised clinical trial. J Diabetes Complications 37:108472. https:\/\/doi.org\/10.1016\/j.jdiacomp.2023.108472","journal-title":"J Diabetes Complications"},{"key":"7430_CR17","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/jdi.14219","volume":"15","author":"R Suzuki","year":"2024","unstructured":"Suzuki R, Amadid H, Major-Pedersen A, Yabe D (2024) Pioneer real Japan: baseline characteristics of a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan. J Diabetes Investig 15:1047\u20131056. https:\/\/doi.org\/10.1111\/jdi.14219","journal-title":"J Diabetes Investig"},{"key":"7430_CR18","unstructured":"Novo Nordisk A\/S. Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS). ClinicalTrials.gov identifier: NCT03811561. https:\/\/clinicaltrials.gov\/study\/NCT03811561"},{"issue":"8","key":"7430_CR19","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.jdiacomp.2024.108692","volume":"36","author":"DM Nathan","year":"2013","unstructured":"Nathan DM, Buse JB et al (2013) Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36(8):2254\u20132261. https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108692","journal-title":"Diabetes Care"},{"key":"7430_CR20","doi-asserted-by":"publisher","first-page":"103099","DOI":"10.1016\/j.dsx.2024.103099","volume":"18","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wei JC, Shih YH, Hung YT, Hsu TJ, Hsu CC et al (2024) Glucagon-like peptide-1 receptor agonists and risk of sight-threatening retinopathy in Taiwanese population: a propensity based cohort study. Diabetes Metab Syndr 18:103099. https:\/\/doi.org\/10.1016\/j.dsx.2024.103099","journal-title":"Diabetes Metab Syndr"},{"key":"7430_CR21","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","volume":"277","author":"M Lakhani","year":"2025","unstructured":"Lakhani M, Kwan ATH, Mihalache A, Popovic MM, Nanji K, Xie JS et al (2025) Association of glucagon-like peptide-1 receptor agonists with optic nerve and retinal adverse events: a population-based observational study across 180 countries. Am J Ophthalmol 277:148\u2013168. https:\/\/doi.org\/10.1016\/j.ajo.2025.05.007","journal-title":"Am J Ophthalmol"},{"key":"7430_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004507","author":"R Talebi","year":"2025","unstructured":"Talebi R, Fortes BH, Yu F, Coleman AL, Tsui I (2025) Real-world associations between GLP-1 receptor agonist use and diabetic retinopathy accounting for longitudinal glycemic control. Retina. https:\/\/doi.org\/10.1097\/IAE.0000000000004507","journal-title":"Retina"},{"key":"7430_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.oret.2024.05.003","volume":"8","author":"AJ Barkmeier","year":"2024","unstructured":"Barkmeier AJ, Herrin J, Swarna KS, Deng Y, Polley EC, Umpierrez GE et al (2024) Comparative effectiveness of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, and sulfonylureas for sight-threatening diabetic retinopathy. Ophthalmol Retina 8:943\u2013952. https:\/\/doi.org\/10.1016\/j.oret.2024.05.003","journal-title":"Ophthalmol Retina"},{"key":"7430_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.07.019","author":"AJ Barkmeier","year":"2025","unstructured":"Barkmeier AJ, Deng Y, Swarna KS, Herrin J, Polley EC, Umpierrez GE et al (2025) Risk of sight-threatening diabetic retinopathy with glucagon-like peptide-1 receptor agonist use in routine clinical practice: comparative effectiveness of semaglutide, dulaglutide, liraglutide, and exenatide. Ophthalmol Retina. https:\/\/doi.org\/10.1016\/j.oret.2025.07.019","journal-title":"Ophthalmol Retina"},{"key":"7430_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/09286586.2024.2399764","volume":"32","author":"Z Tauqeer","year":"2025","unstructured":"Tauqeer Z, Bracha P, Hua P, Yu Y, Cui QN, VanderBeek BL (2025) Glucagon-like peptide-1 receptor agonists are not associated with an increased risk of progressing to vision-threatening diabetic retinopathy. Ophthalmic Epidemiol 32:390\u2013393. https:\/\/doi.org\/10.1080\/09286586.2024.2399764","journal-title":"Ophthalmic Epidemiol"},{"key":"7430_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4093\/dmj.2022.0221","volume":"47","author":"TY Lin","year":"2023","unstructured":"Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ et al (2023) Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J 47:394\u2013404. https:\/\/doi.org\/10.4093\/dmj.2022.0221","journal-title":"Diabetes Metab J"},{"key":"7430_CR27","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.endmts.2024.100168","volume":"15","author":"H Stevens","year":"2024","unstructured":"Stevens H, de la Paz M, Cooper B, Bhattacharya R (2024) Long\u2011term use of semaglutide and risk of diabetic retinopathy progression. Endocr Metab Sci 15:100168. https:\/\/doi.org\/10.1016\/j.endmts.2024.100168","journal-title":"Endocr Metab Sci"},{"key":"7430_CR28","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1464-5491.2008.02650.x","volume":"26","author":"AM Brooks","year":"2009","unstructured":"Brooks AM, Lissett CA (2009) A dramatic deterioration in diabetic retinopathy with improvement in glycated haemoglobin (HbA1c) on exenatide treatment. Diabet Med 26:190. https:\/\/doi.org\/10.1111\/j.1464-5491.2008.02650.x","journal-title":"Diabet Med"},{"key":"7430_CR29","doi-asserted-by":"publisher","first-page":"5834769","DOI":"10.1155\/crop\/5834769","volume":"2024","author":"D Cool","year":"2024","unstructured":"Cool D, Coventon J, Sharma A (2024) Semaglutide inducing resolution of proliferative diabetic retinopathy: A case report. Case Rep Ophthalmol Med 2024:5834769. https:\/\/doi.org\/10.1155\/crop\/5834769","journal-title":"Case Rep Ophthalmol Med"},{"key":"7430_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00592-013-0506-6","volume":"51","author":"V Sarao","year":"2014","unstructured":"Sarao V, Veritti D, Lanzetta P (2014) Regression of diabetic macular edema after subcutaneous exenatide. Acta Diabetol 51:505\u2013508. https:\/\/doi.org\/10.1007\/s00592-013-0506-6","journal-title":"Acta Diabetol"},{"key":"7430_CR31","doi-asserted-by":"publisher","first-page":"109039","DOI":"10.1016\/j.jdiacomp.2025.109039","volume":"39","author":"S Gullaksen","year":"2025","unstructured":"Gullaksen S, Vernstrom L, Sorensen SS, Funck KL, Petersen L, Bek T et al (2025) Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: a post-hoc analysis from a randomised trial. J Diabetes Complicat 39:109039. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109039","journal-title":"J Diabetes Complicat"},{"key":"7430_CR32","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577\u20131589. https:\/\/doi.org\/10.1056\/NEJMoa0806470","journal-title":"N Engl J Med"},{"key":"7430_CR33","doi-asserted-by":"publisher","first-page":"154031","DOI":"10.1016\/j.metabol.2019.154031","volume":"103","author":"MA Nauck","year":"2020","unstructured":"Nauck MA (2020) The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism 103:154031. https:\/\/doi.org\/10.1016\/j.metabol.2019.154031","journal-title":"Metabolism"},{"key":"7430_CR34","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/eurjpc\/zwac315","volume":"30","author":"CE Lim","year":"2023","unstructured":"Lim CE, Pasternak B, Eliasson B, Danaei G, Ueda P (2023) Use of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA\/EASD consensus report in a national population of patients with type 2 diabetes. Eur J Prev Cardiol 30:634\u2013643. https:\/\/doi.org\/10.1093\/eurjpc\/zwac315","journal-title":"Eur J Prev Cardiol"},{"key":"7430_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","volume":"128","author":"ZL Teo","year":"2021","unstructured":"Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N et al (2021) Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology 128:1580\u20131591. https:\/\/doi.org\/10.1016\/j.ophtha.2021.04.027","journal-title":"Ophthalmology"},{"key":"7430_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.visres.2017.03.003","volume":"139","author":"SK Lynch","year":"2017","unstructured":"Lynch SK, Abramoff MD (2017) Diabetic retinopathy is a neurodegenerative disorder. Vision Res 139:101\u2013107. https:\/\/doi.org\/10.1016\/j.visres.2017.03.003","journal-title":"Vision Res"},{"key":"7430_CR37","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.13339","volume":"20","author":"JB Hebsgaard","year":"2018","unstructured":"Hebsgaard JB, Pyke C, Yildirim E, Knudsen LB, Heegaard S, Kvist PH (2018) Glucagon-like peptide-1 receptor expression in the human eye. Diabetes Obes Metab 20:2304\u20132308. https:\/\/doi.org\/10.1111\/dom.13339","journal-title":"Diabetes Obes Metab"},{"key":"7430_CR38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1167\/iovs.62.4.12","volume":"62","author":"Y Zhang","year":"2021","unstructured":"Zhang Y (2021) Glp-1 analogs reduce retinal vascular leakage and inflammation in diabetic models. Invest Ophthalmol Vis Sci 62:12. https:\/\/doi.org\/10.1167\/iovs.62.4.12","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"7430_CR39","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","volume":"66","author":"J Goldney","year":"2023","unstructured":"Goldney J, Sargeant JA, Davies MJ (2023) Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy. Diabetologia 66:1832\u20131845. https:\/\/doi.org\/10.1007\/s00125-023-05988-3","journal-title":"Diabetologia"},{"key":"7430_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1034\/j.1600-0420.1999.770511.x","volume":"77","author":"M Henricsson","year":"1999","unstructured":"Henricsson M, Nilsson A, Janzon L, Groop L (1999) The effect of rapid glycemic control on retinopathy in type 2 diabetic patients: A 5-year follow-up study. Acta Ophthalmol Scand 77:523\u2013528. https:\/\/doi.org\/10.1034\/j.1600-0420.1999.770511.x","journal-title":"Acta Ophthalmol Scand"},{"key":"7430_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11892-018-1094-0","volume":"18","author":"CF Chou","year":"2018","unstructured":"Chou CF, Sherrod CE, Zhang X, Barker L, Bullard KM (2018) Early worsening of diabetic retinopathy in the era of intensive glycemic control. Curr Diab Rep 18:138. https:\/\/doi.org\/10.1007\/s11892-018-1094-0","journal-title":"Curr Diab Rep"},{"key":"7430_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P et al (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (duration-2): a randomised trial. Lancet 376:431\u2013439. https:\/\/doi.org\/10.1016\/S0140-6736(10)60590-9","journal-title":"Lancet"},{"key":"7430_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15367","author":"O Igweokpala","year":"2024","unstructured":"Igweokpala O (2024) Incretin-based therapies and the risk of diabetic retinopathy: a systematic review and meta-analysis. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/dom.15367","journal-title":"Diabetes Obes Metab"},{"key":"7430_CR44","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/bjophthalmol-2012-302005","volume":"96","author":"R Simo","year":"2012","unstructured":"Simo R, Hernandez C, European Consortium for the Early Treatment of Diabetic R (2012) Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 96:1285\u20131290. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302005","journal-title":"Br J Ophthalmol"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07430-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07430-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:07:59Z","timestamp":1785557279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07430-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":44,"alternative-id":["7430"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07430-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study is a systematic review of previously published data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}